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DOI 10.1186/s40478-015-0199-xRESEARCH Open AccessAmyloid accelerates tau propagation and toxicity
in a model of early Alzheimer’s disease
Amy M Pooler1,2, Manuela Polydoro1, Eduardo A Maury1, Samantha B Nicholls1, Snigdha M Reddy1, Susanne Wegmann1,
Christopher William1, Lubna Saqran1, Ozge Cagsal-Getkin1, Rose Pitstick3, David R Beier4, George A Carlson3,
Tara L Spires-Jones1,5 and Bradley T Hyman1*Abstract
Introduction: In early stages of Alzheimer’s disease (AD), neurofibrillary tangles (NFT) are largely restricted to the
entorhinal cortex and medial temporal lobe. At later stages, when clinical symptoms generally occur, NFT involve
widespread limbic and association cortices. At this point in the disease, amyloid plaques are also abundantly
distributed in the cortex. This observation from human neuropathological studies led us to pose two alternative
hypotheses: that amyloid in the cortex is permissive for the spread of tangles from the medial temporal lobe, or
that these are co-occurring but not causally related events simply reflecting progression of AD pathology.
Results: We now directly test the hypothesis that cortical amyloid acts as an accelerant for spreading of tangles
beyond the medial temporal lobe. We crossed rTgTauEC transgenic mice that demonstrate spread of tau from
entorhinal cortex to other brain structures at advanced age with APP/PS1 mice, and examined mice with either
NFTs, amyloid pathology, or both. We show that concurrent amyloid deposition in the cortex 1) leads to a dramatic
increase in the speed of tau propagation and an extraordinary increase in the spread of tau to distal brain regions,
and 2) significantly increases tau-induced neuronal loss.
Conclusions: These data strongly support the hypothesis that cortical amyloid accelerates the spread of tangles
throughout the cortex and amplifies tangle-associated neural system failure in AD.
Keywords: Neurofibrillary tangles, Amyloid plaques, Alzheimer’s disease, Tauopathy, AggregationIntroduction
Progressive accumulation of protein aggregates through-
out the brain is a hallmark of Alzheimer’s disease (AD).
Amyloid plaques, distributed throughout neocortical areas
[27], occur in perhaps a third to half of individuals over
age 65 [15,3]. Tau inclusions, called neurofibrillary tangles
(NFT), occur nearly universally in individuals over the age
of 65, but are nearly always limited to entorhinal cortex
(EC) and closely associated regions unless amyloid plaques
also occur, when the pattern of tangles can extend to other
limbic areas and association cortices [3,11,1]. The extent
of symptoms due to Alzheimer’s disease is closely corre-
lated with the anatomical extent and number of tangles in
the cortex [12]. This set of observations led us to pose two* Correspondence: bhyman@mgh.harvard.edu
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unless otherwise stated.alternative hypotheses: 1) the presence of plaques is per-
missive for, or at least a critical enhancer of, the mechan-
ism that leads to spread of NFT to the cortex, or 2) NFT
and plaque evolution occurs as the disease progresses, but
their progression is not causally related to one another.
Recent data from the rTauEC transgenic mouse model
in which human P301L mutant tau overexpression
uniquely in the EC leads, at advanced age (24 months), to
the appearance of numerous human tau containing NFT
in synaptically connected brain regions suggests that tau
spreading can occur by transfer of misfolded human tau
protein between neurons [6,10,16]. This model affords an
opportunity to directly test the hypothesis that cortical
amyloid deposits accelerate the spread of NFT across cor-
tical areas. We crossed rTgTauEC mice with a model that
exhibits wide-spread cortical Aβ plaque deposition to pro-
duce a APP/PS1 x rTauEC line. We examined brains at
16 months, an age prior to the expected tau propagationThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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from the EC to synaptically-connected regions in the
rTgTauEC x APP/PS1 mice, compared to almost no
propagation of NFT (at this age) in the parental rTgTauEC
line. In addition, the rTgTauEC x APP/PS1 mice exhibited
exacerbated neuritic dystrophies, and importantly, degen-
eration of tau expressing neurons in the EC, a substantially
more severe phenotype than observed in age-matched
rTauEC mice. The data presented here support the hy-
pothesis that the presence of amyloid in the neocortex
acts as an accelerant for tau toxicity and propagation.
Materials and methods
Experimental design
The objective of this study was to determine cortical
amyloid deposition acts as an accelerant for spreading of
neurofibrillary tangles beyond the medial temporal lobe
in AD. We generated a new transgenic mouse model of
AD by crossing mice expressing pathological human tau
in the entorhinal cortex with APP/PS1 mice which
develop widespread amyloid plaques. At 10- and 16-
months of age, we quantified human tau-positive cell bod-
ies, amyloid plaques, cholinergic fiber sprouting, cell death
and axonal dystrophy in brains of these mice. We also
quantified these parameters in mouse lines that expressed
only localized human tau, APP/PS1, or control littermates
expressing only the activator transgene. For all in vivo ex-
periments, n values reported are individual animals.
Animals
Several transgenic mouse lines were used in this study.
Mice with regulatable P301L human tau in the entorhinal
cortex (rTgTauEC) have been characterized previously
[6]. APPswe/PS1dE9 mice (APP/PS1) were obtained
from Jackson Laboratory (stock line B6.Cg-Tg(APPswe,
PSEN1dE9)85Dbo/J). The generation of mice expressing
both APP/PS1 and rTgTauEC (rTgTauEC x APP/PS1) was
described previously [23]. Incipient B6 congenic (4th or 5th
backcross generation with DBA/2 J passenger loci) “S-line”
mice were mated to B6.APP/PS1, which carries C3H/HeJ
passengers. Mice positive for both the EC-tTA and
APP/PS1 transgenes arrays were then crossed to FVB-
Tg(TauP301L)4510 mice to produce rTgTauEC x APP/
PS1 mice. Brains from gender-mixed 10- and 16-month-
old rTgTauEC, APP/PS1 and rTgTauEC x APP/PS1 mice
were used in the present study. As stated above, age-
matched littermates expressing only the activator
transgene were used as human tau-negative controls. All
animal experiments conformed to United States National
Institutes of Health guidelines and were approved by the
Institutional Animal Care and Use Committees of
Massachusetts General Hospital and McLaughlin Re-
search Institute. This article does not contain any studies
with human participants performed by any of the authors.Immunohistochemistry
Mice were sacrificed by CO2 inhalation and brains were
frozen and embedded in M1 mounting medium
(Shandon, Thermo Scientific). 10 mm thick horizontal
brain tissue sections were cut on a cryostat, mounted
on glass slides and stored at −80 C. For immunofluor-
escence labeling, sections were fixed in PBS containing
4% paraformaldehyde for 10 min before being perme-
abilized in 0.1% Triton solution (20 min) and blocked
in 5% normal goat serum (NGS) for 1 h. The following
primary antibodies were diluted in PBS containing
1% NGS: Tau13, monoclonal anti-human tau (1:500),
Covance; Alz50, monoclonal anti-tau, conformation-
dependent (1:100), courtesy of Peter Davies; AW7,
polyclonal anti-Aβ (1:5000), courtesy of Dominic Walsh;
glial fibrillary acidic protein (GFAP; 1:1000), Sigma; and
SMI312, monoclonal anti-neurofilament (1:5000). Sections
were incubated in the appropriate antibody mixture over-
night at 4°C, and then washed thoroughly in Tris-buffered
saline (TBS) before incubation in the appropriate sec-
ondary antibody (1:500), in 1% NGS for 1 h at room
temperature. Secondary antibodies were fluorescent
anti-mouse or anti-rabbit Alexa Fluor 488 (Life Technolo-
gies), Cy3-labeled or Cy5-labeled (Jackson ImmunoRe-
search Laboratories). Sections were counterstained with
DAPI and mounted using antifade mounting medium
(VectaShield). Images were recorded on a Zeiss AxioIma-
ger epifluorescence microscope equipped with a Coolsnap
digital camera and Axio-Vision v4.8 software.
Cell quantification
To determine whether accumulation of tau and Aβ-
induced cell loss in the EC, cell nuclei were quantified in
brains of rTgTauEC and rTgTauEC x APP/PS1 mice at
16 months of age. In four sections for each animal,
DAPI labeled nuclei in layer II of the EC were counted
applying thresholding and particle counting plugins
using Fiji (National Institutes of Health).
Acetylcholinesterase assay
To visualize cholinergic fibers in the DG, 10 mm frozen
brain sections mounted on slides were brought to room
temperature and incubated overnight in 0.68% sodium
acetate buffer (pH 5.0) containing 0.075% glycine, 0.05%
cupric sulfate, 0.12% acetyl thiocholine iodide (freshly
prepared), and 0.0072% ethopropazine. Reactions were
performed overnight at room temperature. Following
incubation, the sections were rinsed five times with
distilled water, incubated in 1.25% sodium sulfide so-
lution (pH 6, freshly prepared) for 30 min at room
temperature, then washed five times with distilled
water, and incubated in 1% silver nitrate solution for
10 min, and finally washed with distilled water. Finally,
slides were dehydrated in a graded series of ethanols
Pooler et al. Acta Neuropathologica Communications  (2015) 3:14 Page 3 of 11and xylene, air dried and coverslipped. Images for fig-
ures were collected on an upright Olympus BX51
microscope (Olympus America).Fluorescence in situ hybridization (FISH)
FISH with co-immunohistochemistry was performed as
previously described [6]. mRNA probe templates for hu-
man tau were generated by RT-PCR from human brain
tissue and correspond to the 3’ untranslated regions of
mouse Mapt (NM_001038609.1; nucleotides 1606–2588)
and human Mapt (NM_016835; nucleotides 2773–3602).Amyloid plaque quantification
Amyloid deposition was assessed using Ab immunofluor-
escence labeling of 10 μm brain sections from APP/PS1
and rTgTauEC x APP/PS1 mice (as described above).
Regions of interest were outlined manually on captured
images using Fiji. These regions were then subjected to a
macro which automatically thresholded and quantified the
size and number of the plaques. Four brain sections were
averaged for the mean average of each animal.Aβ elisa
To determine concentrations of Aβ1–40, 12-month-old
Tg4510 mouse brains (cortex and hippocampus) were
homogenized in TBS containing protease inhibitors
(Complete, Roche). Concentrations of Aβ were deter-
mined using the Wako Human/Rat (Mouse) b-Amyloid
(40) ELISA Kit according to the manufacturer’s protocol.Real-time PCR analysis
Total RNA from five rTgTauEC x APP/PS1 and three
APP/PS1 mice was prepared using Trizol reagent (Sigma
Aldrich). RNA integrity was assessed using the Agilent
2100 Bioanalyzer system and Agilent RNA 6000 Pico Kit
(Agilent Technologies). For RT-PCR analysis, All RNA
samples were transcribed into cDNA using SuperScript®
III Reverse Transcriptase (Life Sciences) in a 20 μl vol-
ume. The abundance of transcripts in cDNA samples
was measured by RT-PCR on Bio-Rad I-cycler with RT2
qPCR Primer Assay for Human APP (SABiosciences)
following the manufacturer’s recommendations. The
levels of APP expression were normalized to GAPDH.
qPCR data were tested for statistical significance (p ≤ 0.05)
using the two-tailed t-test.Western blot analysis
Brain homogenates from indicated regions were ana-
lyzed by immunoblot as previously described [6], with
antibodies directed against total tau (1:5000, DAKO);
human tau (Tau13, 1:2000, Covance); synapsin I (1:1000,
Millipore); and β-actin (1:5000, Abcam).SNP analysis of mouse lines
rTgTauEC x APP/PS1 mice (N = 11) were genotyped by
GeneSeek (Lincoln, NE) with the MegaMouseUniversal
GenomeArray (MegaMUGA, http://csbio.unc.edu/CCsta-
tus/index.py), which includes up to 77,800 single nucleotide
polymorphism (SNP) markers.
Statistical analysis
Data were analyzed with appropriate statistics including
Student’s t test and one-way ANOVA followed by Tukey
or Dunnett’s post-hoc test where necessary. P values
<0.05 were considered to be statistically significant. Data
are reported as mean ± SEM.
Results
Tau propagation is enhanced in rTgTauEC x APP/PS1
mice compared to rTgTauEC
In rTgTauEC mice, targeted overexpression of human
P301L tau in the EC causes the progressive accumula-
tion of pathological tau aggregates first in the neurons
expressing the transgene, and then in synaptically con-
nected neurons including the granule cells of DG and
CA1/CA3 cells of the hippocampus [6,21]. To determine
whether Aβ pathology alters tau pathology progression
and enhances synaptic tau transmission in these mice,
we produced a rTgTauEC x APP/PS1 mouse line [23] as
described in Materials and Methods. Brain regions of
interest are highlighted in white in a representative hori-
zontal section; layer II of the EC is highlighted in yellow
(Figure 1a). At 16 months, as expected, these mice show
amyloid plaque deposition throughout the brain, and
clear human tau immunostaining in the EC (Figure 1b).
Brains of rTgTauEC x APP/PS1 animals were immunol-
abled and analyzed to examine the detailed pattern of
human tau distribution.
In 16-month-old rTgTauEC mice, we found sparse but
occasional human tau immunopositive inclusions in DG
granule cells (Figure 2a,b), confirming the previously
observed infrequent propagation of human tau in
rTgTauEC mice younger than 24 months [6,21]. By
contrast, rTgTauEC x APP/PS1 mice had substantially
more human tau positive DG granule cells (approxi-
mately 20-fold increase relative to rTgTauEC, p < 0.05)
(Figure 2i,g,j). Human tau that accumulated in granule
cells of the DG was also positive for Alz50, an antibody
that recognizes abnormally folded tau (Figure 2d,h,l).
Furthermore, more human tau was also detected in CA1
hippocampal neurons in rTgTauEC x APP/PS1 than in
rTgTauEC mice (Figure 2c,k), suggesting that the pre-
sence of APP/PS1 accelerates the interneuronal transfer of
tau from the entorhinal cortex into neurons in DG and
CA1. Previously we observed no overt differences in
propagation between groups [23], but this is likely due to
the small number of animals examined in that study, and
a b  
Figure 1 Patterns of human tau protein and deposition of Aβ in transgenic mouse models of AD. (a) Low-magnification view of a
16-month-old rTgTauEC horizontal brain section labeled with DAPI. Regions of interest are outlined in white; layer II of the EC, the primary
expression site for the P301L transgene, is highlighted in yellow (scale bar = 500 μm). (b) rTgTauEC x APP/PS1 mice express human tau protein,
labeled with a human-specific tau antibody Tau13 (green), and have robust deposition of amyloid plaques (anti-Aβ antibody AW7, red) at
16 months of age. DAPI staining for cell bodies appears in blue. No human tau positive neurons are observed in control (neuropsin promotor
only) or APP/PS1 mice, and there is no detectable deposition of amyloid plaques in control or rTgTauEC mice. Scale bar = 500 μm.
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bers of animals per group allowed for quantification of
clear differences between the mouse lines. No difference
in human tau protein expression was detected between
the rTgTauEC and rTgTauEC x APP/PS1 genotypes
(Additional file 1: Figure S1). As expected, no human
tau immunoreactivity was observed in control or APP/
PS1 mice (Figure 1).
Next we examined whether human tau propagates
even further to more distal brain regions in rTgTauEC x
APP/PS1 mice. Strikingly, at 16 months, human tau-
positive neurons were also found in the somatosensory
cortical area (Figure 2m) and accessory olfactory areas
(Figure 2n) where no human tau was observed in
rTgTauEC mice (Figure 2e,f ). While most of the crossed
mice showed marked enhancement of propagation to
the hippocampus, about half of the mice (6 of 13 exam-
ined) showed this effect to a much greater extent. Propa-
gation of tau to these distant brain regions may be
facilitated by direct tau input from neurons in the EC or,
more likely, indirectly across multiple synapses.
To further explore the hypothesis that the presence of
amyloid pathology induces acceleration of trans-synaptictau propagation, we next examined brains of younger
rTgTauEC x APP/PS1 animals. In 10-month-old mice,
human tau pathology, including dystrophic neurites, was
detected in the DG in rTgTauEC x APP/PS1 mice (3 of 7
examined), but not in any rTgTauEC (Figure 2o,p). These
observations suggest that the presence of amyloid path-
ology enhances the trans-synaptic transfer of tau in vivo.
The variability observed in tau propagation in the
rTgTauEC x APP/PS1 mice raised the possibility of a
genetic influence on prion-like spread of tau pathology.
Indeed, although all rTgTauEC x APP/PS1 mice were
highly similar genetically and shared the (FVBxB6)F1
background, the B6.Tg(EC-tTA) transactivator line was
not completely congenic and carried DBA/2 J passenger
genes. More than 20,000 markers distinguished B6 mice
from DBA/2 J and C3H/HeJ, which potentially contami-
nated the Tg(EC-tTA) and Tg(APP/PS1) B6 congenic
strains. However, SNP genotyping provided no evidence
of a non-B6 derived region in the rTgTauEC x APP/PS1
mice that co-segregated with the tau propagation
phenotype, indicating that the variability in tau propa-
gation among mice is unlikely to be due to a Mendelian
genetic trait.
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Figure 2 Propagation of tauopathy along neural circuits is exacerbated by amyloid pathology. Low magnification view of horizontal
sections of 16 month old brains from (a) rTgTauEC and (i) rTgTauEC x APP/PS1 mice, labeled with a human-specific tau antibody Tau13 (green)
and cell bodies stained with DAPI (blue; scale bar = 1 mm), reveal increased propagation of tauopathy in rTgTauEC x APP/PS1 mice compared
with rTgTauEC mice. (b,j) Higher magnification of layers of the DG showing the middle molecular layer (MML) and granule cell layer (GC; scale
bar = 50 μm); and (c,k) CA1 fields of the hippocampus (scale bar = 50 μm) show human-tau positive cells in brain regions synaptically connected
to the EC. Note apparent degeneration of the MML of the DG in rTgTauEC x APP/PS1 mice. In rTgTauEC x APP/PS1 mice, but not rTgTauEC mice,
human tau is observed in brain regions distal to the EC such as somatosensory cortex (e,m) and accessory olfactory areas (f,n; scale bars 100 μm).
(d,l) Immunolabeling for Alz50 (red; scale bar 50 μm), a marker of abnormally folded tau, was evident in neurons in the GC layer of the DG
and increased in rTgTauEC x APP/PS1 mice compared with rTgTauEC mice. Again, loss of Alz50-positive terminals in the MML was observed.
(g,h) Quantification of human tau-positive neurons in the DG granule cells immunolabeled with Tau13 (rTgTauEC, N = 7; rTgTauEC x APP/PS1,
N = 10) or Alz50 (rTgTauEC, N = 7; rTgTauEC x APP/PS1, N = 7) in 16-month-old animals. Significantly more neurons containing human tau were
observed in rTgTauEC x APP/PS1 mice compared with rTgTauEC mice, indicating increased propagation in this group. (o,p) In 10-month-old mice,
human tau propagation (Tau13) from the EC to the DG was observed only in rTgTauEC x APP/PS1 mice (rTgTauEC, N = 7; rTgTauEC x APP/PS1, N = 7).
Values represent mean ± s.e.m; *P < 0.05.
Pooler et al. Acta Neuropathologica Communications  (2015) 3:14 Page 5 of 11The presence of amyloid accelerates synaptic alterations
in the EC of rTgTauEC mice
Previous characterization of the rTgTauEC mice noted a
marked degeneration of tau-positive terminals in themiddle molecular layer (MML) of the DG after 24 months,
suggesting degeneration of perforant pathway axons that
arise from EC neurons [6]. In the present study, the
MML appeared fairly unremarkable at 16 months in
Pooler et al. Acta Neuropathologica Communications  (2015) 3:14 Page 6 of 11the rTgTauEC mice, whereas rTgTauEC x APP/PS1
mice showed robust degeneration of the tau-positive
terminals in this region (Figure 2b,j), suggesting a pro-
found loss of EC inputs.
In classical deafferentation paradigms, loss of perforant
pathway axons from the EC leads to deafferentation of
their terminal zone in the MML of the DG [14]. Subse-
quently, neighboring acetylcholinesterase (AChE) con-
taining fibers, located in the inner molecular layer react
to the deafferentation by sprouting aberrantly into the
MML [17]. The amount of AChE fiber sprouting into
the MML correlates with the severity of perforant
pathway degeneration and has been detected in
21-month old and more robustly in 24-month old
rTgTauEC mice [20]. Visualization of these fibers was
acheived by histochemical staining for AChE, as
previously described [7,20]. In the present study, we
compared sprouting of AChE-positive fibers into the
MML in 10- and 16-month-old rTgTauEC x APP/PS1,
rTgTauEC, APP/PS1, and non-transgenic control mice.Control APP/PS1rTgTauEC
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either the EC or the hippocampus of the rTgTauEC x
APP/PS1 mice (Additional file 2: Figure S2). We also
found increased expression of GFAP in the EC of
rTgTauEC x APP/PS1 and APP/PS1 mice compared to
rTgTauEC and controls, particularly in the vicinity of
ThioS-positive amyloid plaques (Additional file 3:
Figure S3), indicating widespread astrogliosis in agree-
ment with previous studies of the APP/PS1 line [18].
Increased neuroinflammation in rTgTauEC x APP/PS1
mice may therefore contribute to enhanced tau propa-
gation and EC degeneration relative to rTgTauEC
mice. These data indicate that synergy between APP/
PS1 and human P301L tau enhances degeneration of
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to a profound loss of tau expressing entorhinal cortex
neurons
We determined the expression of the human tau trans-
gene in the rTgTauEC and rTgTauEC x APP/PS1 lines
using fluorescent in situ hybridization (FISH) of 10 μm
horizontal brain sections from 10- and 16-month-old
animals. At 10 months of age, as expected tau transgene
expression displayed a restricted distribution to the
medial EC, with limited expression in the neighboring pre-
and para-subiculum in both rTgTauEC and rTgTauEC x
APP/PS1 mice (Additional file 4: Figure S4). At 16 months
of age, human tau transgene expression in the medial EC
was robust in rTgTauEC mice (Figure 3c). However, unex-
pectedly, rTgTauEC x APP/PS1 mice displayed a nearly
complete reduction in the number of FISH-positive cells
compared with mice expressing rTgTauEC only (Figure 3d, e).
No FISH-positive cells were found in the DG of either
mouse line (Additional file 5: Figure S5), as expected. Co-
labeling of the same brain sections with an anti-human tau
antibody (Tau13) revealed strong immunoreactivity in the
EC in both mouse lines. Closer examination of EC neurons
revealed that a proportion of neurons were immunoreactive
for Tau13 but negative for human tau mRNA (Figure 3c),
confirming previous findings that tau protein is able to
transfer between neurons in this mouse model [6]. How-
ever, significantly fewer EC neurons were positive for both
human tau mRNA and protein in the rTgTauEC x APP/
PS1 compared to rTgTauEC mice (Figure 3e), and there
was overall a loss of >90% of tau mRNA expressing neu-
rons. Quantification of the total number of cells in layer II
of EC revealed significantly fewer cells in rTgTauEC x APP/
PS1 mice compared with rTgTauEC mice (Figure 3f), sug-
gesting that enhanced cell death occurs in mice with both
tau and Aβ pathologies. The magnitude of neuronal loss
appeared smaller when all EC layer II cells, and not only
the tau-containing cells, are quantified since human
tau mRNA expression is limited to a subset of neurons
(approximately 10 – 15%) in layer II of the EC [6].
Together these data demonstrate a profound degeneration
of transgene-expressing neurons in the rTgTauEC x APP/
PS1 mice.
Tau expression in the entorhinal cortex impacts
characteristics of amyloid deposition
Axonal dystrophy in the vicinity of amyloid plaques, as a
result of amyloid-beta toxicity, has been described in
both mouse models [4] and human brain affected by AD
[19]. To examine whether the presence of human tau
enhances amyloid toxicity, we quantified dystrophic
axons within amyloid plaques in the MML in 16-month-
old APP/PS1 and rTgTauEC x APP/PS1 mice. Axonal dys-
trophies were immunolabeled using an antibody against
phosphorylated neurofilament proteins (SMI312) that arepresent in dystrophic axons, and amyloid plaques were
stained with the anti-amyloid antibody AW7 (Figure 4a).
The presence of abnormally folded tau was detected with
Alz50. Counting SMI312-positive punctae within amyloid
plaques we detected a significant increase in axonal dys-
trophies in the MML of rTgTauEC x APP/PS1 compared
with to APP/PS1 mice (Figure 4b), and in rTgTauEC x
APP/PS1 mice the amount of abnormally folded tau corre-
lated linearly (r2 = 0.44) with the number of dystrophic
punctae in a plaque (Figure 4b). Taken together, our data
suggest that the presence of pathological tau exacerbates
amyloid-induced axonal defects.
Presence of tau may impact amyloid plaque burden
Since human P301L tau appeared to aggravate amyloid
toxicity, we next asked whether pathological tau also
enhances amyloid plaque formation. In horizontal
brain sections of 10- and 16-month-old APP/PS1 and
rTgTauEC x APP/PS1 mice, we immunolabeled pla-
ques using the anti- Aβ antibody AW7 and deter-
mined amyloid plaque number and size in both the EC
and the somatosensory cortex (Figure 5a). In 10-
month-old mice, when compared to APP/PS1 mice,
rTgTauEC x APP/PS1 mice showed an increase in
plaque area (significant, p = 0.022) but plaque number
did not reach significance (p = 0.087) in the EC, and
no change was observed in somatosensory cortex
(Figure 5b). At 16 months of age, both entorhinal and
somatosensory cortex, rTgTauEC x APP/PS1 mice had
significantly more amyloid plaques than APP/PS1
mice. Image analysis suggested that these plaques were
also significantly larger (Figure 5b). By performing
qPCR on brain tissue from adjacent brain sections we
confirmed that the difference in amyloid burden
between rTgTauEC x APP/PS1 and APP/PS1 mice did
not originate from differential expression of the hu-
man APP transgene (Figure 5c).
Discussion
In AD, both NFT and plaques appear in the cortex, but
whether this is co-occurrence of two separate lesions or
if there is a pathophysiological interaction between pla-
ques and tangles is unknown. On the basis of well-
established patterns of human neuropathological stages
of AD, we considered two possibilities: that the presence
of plaques in the cortex might accelerate or enhance the
“spread” of tangles from the medial temporal lobe to the
cortex, or that they are independent events co-occurring
during disease progression. The present findings show
that the presence of amyloid pathology exacerbates the
spread of tau from neurons in the EC to synaptically-
connected brain regions. The mouse models presented
in this study permitted us to visualize the progression of
tau pathology in the presence or absence of widespread
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occurring early in AD. We examined the consequence of
the co-occurrence of these lesions on tau propagation
and toxicity. Our results indicate that the presence of
Aβ deposition 1) significantly promotes trans-neuronal
propagation of tau pathology, and 2) accelerates degen-
eration of human tau-expressing neurons. Furthermore,
accumulation of human tau also impacts amyloid path-
ology, by exacerbating plaque-related axonal dystrophy
and increasing Aβ plaque burden. Together, our data
imply a synergistic reinforcement between tau and amyl-
oid pathology in AD, with a dramatic order of magni-
tude increase in tau propagation and toxicity in the
presence of Aβ.
In rTgTauEC x APP/PS1 mice, tau-positive neurons in
the DG were increased approximately 20-fold compared
to modest levels of tau propagation in the parental
rTauEC line, at 16 months of age. Furthermore, 16 month
old rTgTauEC x APP/PS1 mice demonstrate propagationof tau aggregates to more distal regions, such as the
accessory olfactory areas, olfactory bulb and frontal corti-
ces, areas only marginally involved even at 24 months in
rTauEC mice. Thus, it appears that the presence of amyl-
oid accelerates the interneuronal transfer of tau. The
mechanism of this enhancement of tau related phenotypes
is not clear. For example, the presence of amyloid may
alter the regulated release of tau into extracellular space
[22,29] or promote its specific uptake [28] by synaptically-
connected neurons, and these actions may be further
exacerbated by neuroinflammation. We conclude that
the presence of neocortical amyloid deposits is part of
a causal chain that leads to augmentation of the NFT
trans-synaptic propagation phenotype.
Equally importantly, profound loss of EC layer II neu-
rons was observed in 16 month old rTgTauEC x APP/
PS1 mice, again in contrast to no detectable loss of these
tau expressing neurons in the parenteral rTauEC line at
this age. Taken together, our current data suggest that
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EC cytotoxicity and subsequent perforant path degener-
ation in AD.
In addition to asking whether amyloid pathology af-
fects the progression of tau pathology, we also compared
the rTgTauEC x APP/PS1 and APP/PS1 mouse lines to
assess the impact of human tau on amyloid deposition.
Although the amyloid cascade hypothesis postulates that
Aβ is the initiator of the pathological cascade of AD [9],
very recent meta-analyses of pathophysiological bio-
markers of AD suggest that Aβ and tau may be partly
independent of each other and interact synergistically
[13,5]. Indeed, in the present study we found that the
presence of human tau exacerbated plaque-inducedneuritic dystrophy, indicating that tau can enhance
amyloid deposition and toxicity. In preliminary stud-
ies, we also measured Aβ concentrations in brains of
rTg4510 mice, a related mouse line that expresses hu-
man P301L tau throughout the forebrain and displays
robust NFT pathology [26]. We found that the con-
centration of endogenous mouse Aβ was significantly
higher in rTg4510 mice, in both the cortex and the
hippocampus (Additional file 6: Figure S6) compared
to wild-type mice. These data suggest that the pres-
ence of pathogenic tau may enhance accumulation of
Aβ peptide, in concert with earlier work that found in-
creased amyloid burden in mice overexpressing both hu-
man mutant APP and tau [25]. Although the mechanisms
Pooler et al. Acta Neuropathologica Communications  (2015) 3:14 Page 10 of 11by which tau might influence Aβ deposition require fur-
ther investigation, our data demonstrating increased Aβ
concentrations in a tauopathy mouse line suggest that the
presence of pathological tau can increase Aβ.Conclusions
Several previous observations have suggested a link be-
tween tau and Aβ in mouse models [24,25,2,8] - for ex-
ample, injection of tau overexpressing mice with brain
extract from APP23 mice increased tau deposition; and
injection of Aβ1–42 fibrils into P301L tau-expressing
mice induced NFT deposits. the current results extend
these data, and suggest a specific effect of Aβ on tau
propagation and toxicity, in a way that directly models
the disease progression in human patients. Neuropatho-
logical studies suggest that although entorhinal NFT are
nearly universal after the age of 65 – and detectable as
early as age 40 [3] – with increased NFT number and
wider distribution with increasing age and the co-
occurrence of Aβ deposits in the cortex. Together, these
data support a model in which the presence of amyloid
in neocortical projection target zones accelerates the
propagation of tau across neural circuits, as well as en-
hancing the toxicity of tau as assessed by neuritic
changes and even neuronal death, in agreement with
hypotheses derived from observation of post-mortem
human brain. These results thus contrast with predic-
tions of the linear amyloid hypothesis in which amyloid
toxicity causes tau related changes; instead, these data
favor a model in which amyloid acts synergistically to ac-
celerate tau propagation and toxicity, which, in this model,
is an independently-driven process. The rTgTauEC x APP/
PS1 mice thus provide a model in which to further test
tau-Aβ interactions, and to better understand underlying
mechanisms whereby tau propagation is accelerated.Additional files
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